Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

The FDA Fast-Tracked Psychedelic Medicines For Depression And PTSD

The Food and Drug Administration has fast-tracked three psychedelic medicines for review, issuing priority vouchers to companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone, a compound related to MDMA, for post-traumatic stress disorder, in a development that could put the first FDA-approved psychedelic medicines on the market as soon as this summer. The vouchers compress the agency’s standard review timeline from the usual 10 to 12 months down to just one to two months, a change the FDA Commissioner said is designed to ensure that red tape does not delay treatments that show genuine promise for conditions that have been notoriously difficult to treat. The three companies that received vouchers are Compass Pathways, the nonprofit Usona Institute, and Otsuka Pharmaceutical, which is acquiring the methylone program. The action followed an executive order signed by President Trump directing the FDA to prioritize psychedelic drugs that have received Breakthrough Therapy designation, a status reserved for treatments showing early evidence of substantial improvement over existing options.

For millions of Americans with treatment-resistant depression, PTSD, and other serious mental health conditions that have not responded to available medications, the move represents a potential turning point in access to a category of medicine that has shown significant clinical results but has remained largely inaccessible for decades. Psilocybin has shown durable antidepressant effects in multiple studies, with some patients maintaining improvement for at least a year after a single treatment course. The FDA also cleared the first-ever clinical study in the United States of noribogaine, a compound derived from the ibogaine plant, as a potential treatment for alcohol use disorder, a condition that affects more than 29 million Americans. The FDA Commissioner said the first psychedelic drug could receive approval by the end of summer, and that the field is moving forward grounded in sound science and rigorous clinical standards.

Source: https://edition.cnn.com/2026/04/24/health/fda-psychedelic-drugs-priority-vouchers

PrevPreviousJurassic Park Star Sam Neill Is Cancer Free
NextBanksy Just Confirmed His Latest Masterpiece, And London Is Already Crowding Around ItNext

Recent Articles

Happy News

Scientists May Have Finally “Seen” Dark Matter

May 9, 2026

For nearly a century, dark matter has been one of the greatest mysteries in all of science. We know it exists as it makes up an estimated 85% of the universe’s total mass and acts as invisible gravitational scaffolding holding galaxies together, but no one has ever directly observed it.

Read More
Happy News

Coral Reefs Are Hiding An Almost Entirely Unstudied Universe Of Potential Medicine

May 9, 2026

Scientists at the University of Galway and an international consortium have discovered that coral reefs contain an almost entirely unstudied universe of microbial life, publishing a study in Nature that reconstructed the genomes of 645 microbial species from 99 coral reefs across 32 Pacific islands, with more than 99 percent

Read More
Happy News

A Rare Superbloom Is Turning Part Of Redwood National Park Purple And There Are Only Weeks To See It

May 9, 2026

Something extraordinary and fleeting is happening right now in Northern California, where the Bald Hills grasslands above the redwood canopy in Redwood National Park have erupted into a rare lupine superbloom, turning a stretch of elevated landscape off a remote road near Orick into a sweeping sea of purple, blue,

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.